Fortress Biotech forms a new subsidiary, Caelum Biosciences, Inc., to develop a novel treatment for AL Amyloidosis

Download the Press Release (PDF) Caelum Program Evaluating CAEL‐101 (11‐1F4) for AL Amyloidosis In‐licensed from Columbia University Data from ongoing Phase 1a/1b study of CAEL‐101 presented by Dr. Suzanne Lentzsch at ASH have demonstrated CAEL‐101 is safe and well tolerated; 67 percent of patients showed improvement in organ function. Michael Spector to Serve as Chief Executive Officer NEW YORK, NY – January 4, 2017 – Fortress Biotech, Inc. (Nasdaq: FBIO)

Read More